Novartis Ag (NVSEF) Change in Account Payables (2020 - 2025)
Historic Change in Account Payables for Novartis Ag (NVSEF) over the last 6 years, with Q1 2025 value amounting to -$172.0 million.
- Novartis Ag's Change in Account Payables rose 5794.62% to -$172.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was -$236.0 million, marking a year-over-year decrease of 15652.17%. This contributed to the annual value of -$297.0 million for FY2024, which is 2857.14% down from last year.
- Per Novartis Ag's latest filing, its Change in Account Payables stood at -$172.0 million for Q1 2025, which was up 5794.62% from -$297.0 million recorded in Q4 2024.
- Novartis Ag's 5-year Change in Account Payables high stood at $87.0 million for Q1 2023, and its period low was -$409.0 million during Q1 2024.
- Moreover, its 5-year median value for Change in Account Payables was -$68.0 million (2022), whereas its average is -$139.5 million.
- In the last 5 years, Novartis Ag's Change in Account Payables crashed by 216666.67% in 2022 and then skyrocketed by 22985.07% in 2023.
- Over the past 5 years, Novartis Ag's Change in Account Payables (Quarter) stood at -$4.0 million in 2021, then tumbled by 1575.0% to -$67.0 million in 2022, then plummeted by 244.78% to -$231.0 million in 2023, then fell by 28.57% to -$297.0 million in 2024, then skyrocketed by 42.09% to -$172.0 million in 2025.
- Its Change in Account Payables was -$172.0 million in Q1 2025, compared to -$297.0 million in Q4 2024 and -$290.0 million in Q3 2024.